权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Precision Medicine for the Peripheral Nervous System Disorder Familiar Dysautonomia

周围神经系统疾病（熟悉的自主神经功能障碍）的精准医学

基本信息

批准号：
10320798
负责人：
Nadja Zeltner
金额：
$ 37.75万
依托单位：
UNIVERSITY OF GEORGIA
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-12-15 至 2025-11-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10320798
关键词：
Actins Affect Afferent Neurons Age Animal Model Autonomic nervous system Binding Brain Cadherins Cell Count Cell Line Cells Chemicals Childhood Chinese Traditional Medicine Crosslinker Cytoskeleton DNA Sequence Defect Development Disease Dysautonomias Extracellular Matrix Extracellular Matrix Proteins Familial Dysautonomia Familial disease Frequencies Functional disorder Future Genes Genetic Goals Heart Rate Human In Vitro Kinetics Knowledge Laminin Lead Light Longitudinal Studies Modeling Modification Molecular Mutation Neurodegenerative Disorders Neurons Nociceptors Pain Pathway interactions Patients Peripheral Nervous System Peripheral Nervous System Diseases Pharmaceutical Preparations Phenotype Point Mutation Population Property Proteins Reporting Research Research Personnel Sampling Sensory Severities Severity of illness Symptoms Testing Tissues Transcription Elongation Transfer RNA Vomiting Work blood pressure regulation crosslink effective therapy exome sequencing genipin human disease human pluripotent stem cell improved induced pluripotent stem cell insight novel pain sensation precision medicine stem cell technology tool

项目摘要

Project summary/Abstract Familial Dysautonomia represents a rare, particularly devastating form of a peripheral nervous system (PNS) disorder. Defective development and degeneration of the sensory and autonomic nervous system in FD patients leads to symptoms including decreased sensitivity to pain and difficulty regulating blood pressure or heart rate. Some FD patients can have very severe symptoms, while others have much milder symptoms. Interestingly, this is the case despite the fact that 99.5% of all patients carry a homozygous mutation in the gene ELP1 (previously IKBKAP). ELP1 protein is involved in transcriptional elongation and tRNA modification, amongst other functions, and the mutation specifically affects PNS tissues. There are no approved drugs for FD available and patients’ symptoms are merely managed. There is a critical need for a deeper understanding of the mechanistic underpinning of FD for the development of precise and effective treatments. To understand why there is this discrepancy of severity in FD, we employed the human pluripotent stem cell (hPSC) technology and successfully recapitulated phenotypes in vitro that captured varying disease severity seen in patients. For example, decreased sensation of pain was captured by the development of decreased numbers of sensory neurons derived from severe FD PSCs. This model further allowed us to identify three potential modifier mutations in LAMB4, KIAA1211 and FAT2, an extra cellular matrix (ECM) protein, actin regulator and cadherin, respectively. These were present in severe FD patients only and were absent in mild patients. Thus, we established the basis for a new paradigm in FD research that FD may consist of two genetically distinct sub-diseases. In preliminary studies, we were able to employ this model to conduct a chemical screen that allowed us to identify a compound called genipin that was able to rescue the severe FD phenotype. Here, we propose to expand on our previous discoveries and define the molecular mechanism behind severe FD. In Aim 1, we aim to understand the molecular mechanism underlying severe FD. In Aim 2, we investigate the mode of action of genipin and how it may aid us in understanding the mechanism of severe FD as well as be developed as a potential future treatment option for FD patients. We believe our studies may enable us to move the field closer toward precision medicine for FD patients and provide deep molecular insights into the understanding of other PNS disorders.

项目总结/文摘